Patents
Sitemap › C07 - Organic chemistry › C07D - Heterocyclic compounds
More topics under "C07D - Heterocyclic compounds" (1,537,440)
C07D 201 - Preparation, separation, purification, or stabilisation of unsubstituted lactams (2,192)
C07D 203 - Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom (1,097)
C07D 205 - Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom (6,868)
C07D 207 - Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom (40,304)
C07D 209 - Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom (45,780)
C07D 211 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings (37,939)
C07D 213 - Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members (63,273)
C07D 215 - Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems (27,676)
C07D 217 - Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems (11,865)
C07D 219 - Heterocyclic compounds containing acridine or hydrogenated acridine ring systems (2,120)
C07D 221 - Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups (10,931)
C07D 223 - Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom (8,732)
C07D 225 - Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom (1,649)
C07D 227 - Heterocyclic compounds containing rings having one nitrogen atom as the only ring hetero atom, according to more than one of groups (473)
C07D 229 - Heterocyclic compounds containing rings of less than five members having two nitrogen atoms as the only ring hetero atoms (515)
C07D 231 - Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings (25,550)
C07D 233 - Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings (34,408)
C07D 235 - Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings (15,325)
C07D 237 - Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings (8,468)
C07D 239 - Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings (42,619)
C07D 241 - Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings (18,673)
C07D 243 - Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms (5,961)
C07D 245 - Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms (898)
C07D 247 - Heterocyclic compounds containing rings having two nitrogen atoms as the only ring hetero atoms, according to more than one of groups (239)
C07D 249 - Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms (17,749)
C07D 251 - Heterocyclic compounds containing 1,3,5-triazine rings (10,913)
C07D 253 - Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group (2,967)
C07D 255 - Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups (739)
C07D 257 - Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms (9,612)
C07D 259 - Heterocyclic compounds containing rings having more than four nitrogen atoms as the only ring hetero atoms (488)
C07D 261 - Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings (11,459)
C07D 263 - Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings (20,978)
C07D 265 - Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms (11,132)
C07D 267 - Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms (2,022)
C07D 269 - Heterocyclic compounds containing rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms according to more than one of groups (111)
C07D 271 - Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms (7,144)
C07D 273 - Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups (2,368)
C07D 275 - Heterocyclic compounds containing 1, 2-thiazole or hydrogenated 1,2-thiazole rings (4,972)
C07D 277 - Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings (33,621)
C07D 279 - Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms (5,149)
C07D 281 - Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms (1,924)
C07D 283 - Heterocyclic compounds containing rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms, according to more than one of groups (102)
C07D 285 - Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups (9,964)
C07D 291 - Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms (1,087)
C07D 293 - Heterocyclic compounds containing rings having nitrogen and selenium or nitrogen and tellurium, with or without oxygen or sulfur atoms, as the ring hetero atoms (553)
C07D 295 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms (34,005)
C07D 301 - Preparation of oxiranes (10,136)
C07D 303 - Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom (12,512)
C07D 305 - Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms (5,442)
C07D 307 - Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom (47,108)
C07D 309 - Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings (12,815)
C07D 311 - Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings (24,127)
C07D 313 - Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom (3,580)
C07D 315 - Heterocyclic compounds containing rings having one oxygen atom as the only ring hetero atom according to more than one of groups (1,360)
C07D 317 - Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms (18,224)
C07D 319 - Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms (10,283)
C07D 321 - Heterocyclic compounds containing rings having two oxygen atoms as the only ring hetero atoms, not provided for by groups (2,079)
C07D 323 - Heterocyclic compounds containing more than two oxygen atoms as the only ring hetero atoms (1,581)
C07D 325 - Heterocyclic compounds containing rings having oxygen as the only ring hetero atom according to more than one of groups (168)
C07D 327 - Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms (2,428)
C07D 329 - Heterocyclic compounds containing rings having oxygen and selenium or oxygen and tellurium atoms as the only ring hetero atoms (47)
C07D 331 - Heterocyclic compounds containing rings of less than five members, having one sulfur atom as the only ring hetero atom (456)
C07D 333 - Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom (32,883)
C07D 335 - Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom (4,725)
C07D 337 - Heterocyclic compounds containing rings of more than six members having one sulfur atom as the only ring hetero atom (875)
C07D 339 - Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms (3,352)
C07D 341 - Heterocyclic compounds containing rings having three or more sulfur atoms as the only ring hetero atoms (281)
C07D 343 - Heterocyclic compounds containing rings having sulfur and selenium or sulfur and tellurium atoms as the only ring hetero atoms (52)
C07D 345 - Heterocyclic compounds containing rings having selenium or tellurium atoms as the only ring hetero atoms (419)
C07D 347 - Heterocyclic compounds containing rings having halogen atoms as ring hetero atoms (38)
C07D 401 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom (107,979)
C07D 403 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group (62,587)
C07D 405 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom (69,397)
C07D 407 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group (11,963)
C07D 409 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms (52,226)
C07D 411 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms (2,465)
C07D 413 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms (64,687)
C07D 415 - Heterocyclic compounds containing the thiamine skeleton (90)
C07D 417 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group (62,773)
C07D 419 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms (1,431)
C07D 421 - Heterocyclic compounds containing two or more hetero rings, at least one ring having selenium, tellurium, or halogen atoms as ring hetero atoms (480)
C07D 451 - Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.02,4] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof (5,273)
C07D 453 - Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids (5,704)
C07D 455 - Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine (2,122)
C07D 457 - Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula: , e.g. lysergic acid (836)
C07D 459 - Heterocyclic compounds containing benz [g] indolo [2, 3-a] quinolizine ring systems, e.g. yohimbine; 16, 18-lactones thereof, e.g. reserpic acid lactone (97)
C07D 461 - Heterocyclic compounds containing indolo [3, 2, 1-d, e] pyrido [3, 2, 1-i, j] [1, 5]-naphthyridine ring systems, e.g. vincamine (286)
C07D 463 - Heterocyclic compounds containing 1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula: , e.g. carbacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring (613)
C07D 471 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups (64,559)
C07D 473 - Heterocyclic compounds containing purine ring systems (11,932)
C07D 475 - Heterocyclic compounds containing pteridine ring systems (2,718)
C07D 477 - Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula: , e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring (2,484)
C07D 487 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups (57,272)
C07D 489 - Heterocyclic compounds containing 4ah-8, 9 c- iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: (2,334)
C07D 491 - Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups , , or (29,726)
C07D 493 - Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system (17,376)
C07D 495 - Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms (21,336)
C07D 497 - Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms (1,069)
C07D 498 - Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms (21,960)
C07D 499 - Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula: , e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring (3,448)
C07D 501 - Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula: , e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring (7,574)
C07D 503 - Heterocyclic compounds containing 4-oxa-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula: , e.g. oxapenicillins, clavulanic acid derivatives; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring (648)
C07D 505 - Heterocyclic compounds containing 5-oxa-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula: , e.g. oxacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring (556)
C07D 507 - Heterocyclic compounds containing a condensed beta-lactam ring system, not provided for by groups , or; Such ring systems being further condensed (161)
C07D 513 - Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups , or (15,120)
C07D 515 - Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups , or (877)
C07D 517 - Heterocyclic compounds containing in the condensed system at least one hetero ring having selenium, tellurium, or halogen atoms as ring hetero atoms (452)
C07D 519 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or (11,041)
C07D 521 - Heterocyclic compounds containing unspecified hetero rings (16,203)
Patents for C07D - Heterocyclic compounds (10,420)
06/2005
06/02/2005CA2546093A1 5-substituted imidazoles
06/01/2005EP1534730A2 Modified transferin-antibody fusion proteins
06/01/2005EP1534717A1 Beta-lactamase inhibitor prodrug
06/01/2005EP1534695A2 Tyrosine kinase inhibitors
06/01/2005EP1534677A1 Piperidine derivatives and their use as selective inhibitors of mip-1alpha binding to its receptor ccr1
06/01/2005EP0991625B1 Inhibitors of factor xa with a neutral p1 specificity group
06/01/2005CN1622946A Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors
06/01/2005CN1204138C Pyrazolo [4, 3-d] pyrimidine derivs.
05/2005
05/31/2005US6900327 Used as antidepressants, to treat obsessive compulsive disorder, panic disorders, bulimia, anorexia, pain, obesity, senile demential, migraines, and social phobias
05/26/2005WO2004108664A3 Bicyclic heterocycles, drugs containing said compounds, the use thereof and method for preparing the same
05/26/2005US20050113373 medicine to inhibit proliferative conditions, such as cancer and psoriasis; detecting or identifying a histone deactylase (HDAC) in a biological sample
05/26/2005US20050113340 9-(Substituted aryl, heteroaryl, alicyclyl, or heterocyclyl)methyl-2-amino-6-halopurines, e.g., 6-chloro-9-(4-methoxy-3,5-dimethyl-pyridin-2-ylmethyl)-9H-purin-2-ylamine; used in the treatment and prevention of various Heat Shock Protein 90 mediated disorders, e.g., proliferative disorders
05/26/2005US20050113339 inflammatory diseases, infections, autoimmune disorders, stroke, ischemia, cardiac disorder, neurological disorders, fibrogenetic disorders, proliferative disorders, tumors, leukemias, neoplasms, cancers, carcinomas, metabolic diseases, and malignant disease
05/25/2005EP1533318A1 Prodrugs of thrombin inhibitors
05/25/2005EP1532122A1 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia
05/25/2005EP0946511B1 Novel compounds with analgesic effect
05/25/2005CN1620438A 5, 6-diaryl-pyrazine-2-amide derivatives as CBI antagonists
05/25/2005CN1620430A 3-phenyl-2-arylalkylthiopropionic acid derivatives as selective agonists of PPAR-alpha
05/25/2005CN1620291A 3-(imidazolyl)-2-alkoxypropanoic acids as TAFIA inhibitors
05/25/2005CN1203065C Non-yellowing para-tertiaryl-alkyl phenyl substituted triazine and pyrimidine ultraviolet light absorbers
05/25/2005CN1203061C Substituted isoquinolines, its preparing process, medical composition and its use for preparing medicine
05/24/2005US6897321 Process for preparing azacycloalkanoylaminothiazoles (LD 137e)
05/24/2005US6897207 Kinase inhibitors; angiogenesis inhibitors, anticancer agents, antiinflammatory agents and chronic obstructive pulmonary disease inhibitors
05/24/2005CA2157792C N-(3-piperidinyl-carbonyl)-beta-alanine derivatives as paf antagonists
05/19/2005WO2005044794A2 Immunohistochemical methods
05/19/2005WO2005044793A2 Nitrogen-containing fused heterocyclic compounds
05/19/2005WO2005044792A2 Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
05/19/2005WO2005044268A1 Preparation of pharmaceutical salts of [1, 4] - bipiperidine
05/19/2005WO2005021496A3 Synthesis of derivatives of ginkgolide c
05/19/2005WO2005016228A3 Compositions and methods for reducing the risk of epileptic occurrence and/or for treatment of seizure disorders
05/19/2005WO2004092123A3 Inhibitors of fungal invasion
05/19/2005WO2004035565A8 Method for the synthesis of a benzimidazole compound
05/19/2005US20050107607 Processes for preparing novel methylene blue derivative
05/19/2005US20050107458 used as diagnostic kits, bioassay and/or drugs for preventing cancers, Alzheimer's disease, amyotrophic lateral sclerosis, Parkinson's disease, stroke, ischaemia, Huntington's disease, epilepsy, multiple sclerosis, neuropathy, or injuries of the brain or spinal chord, or as tyrosine kinase inhibitors
05/19/2005US20050107436 Compounds for inflammation and immune-related uses
05/19/2005US20050107435 antibiotics such as (5S,5S')-N-(3-{4'-[5-(Acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2,2'-difluoro-biphenyl-4-yl}-2-oxo-oxazolidin-5-ylmethyl)-acetamide, used for treating a bacterial infections in mammals
05/19/2005US20050107418 Macrolides
05/19/2005US20050107399 Cytokine inhibitors
05/19/2005US20050107369 Heteroaromatic selective inhibitors of neuronal nitric oxide synthase
05/19/2005US20050107343 Pyrrolo[2,3-d]pyrimidin-2-ylamines substituted in the 7th position by a aryl, heteroaryl, alicyclic, or heterocyclic group connected by methyl, C(O) , C(S) , S(O) or SO2; used in the treatment and prevention of various Heat Shock Protein 90 mediated disorders, e.g., proliferative disorders
05/19/2005CA2544855A1 Immunohistochemical methods
05/19/2005CA2544845A1 Preparation of pharmaceutical salts of [1, 4] - bipiperidine
05/19/2005CA2543707A1 Nitrogen-containing fused heterocyclic compounds
05/19/2005CA2543115A1 Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
05/18/2005EP1530430A2 Method for producing an avocado unsaponifiable rich in furan lipids
05/18/2005CN1617869A 4-(piperidyl- and pyrrolidyl-alkyl-ureido) -quinolines as urotensin ii receptor antagonists
05/18/2005CN1617712A Pharmaceutical nanoparticulate composition of a tachykinin receptor antagonist
05/18/2005CN1202108C Spiro compounds, preparing method and intermediate
05/18/2005CN1202087C Derivatives of acyl-piperazinil-pyrimidins, preparation thereof and application as medicaments
05/17/2005US6894064 Benzothiophenes, formulations containing same, and methods
05/17/2005US6894041 Oxazolyl-acid amide derivatives useful as inhibitors of PDE4 isozymes
05/17/2005CA2347757C Method for producing (+)-exo-6-phenyl-3-azabicyclo-[3.2.0]heptanes
05/12/2005WO2005042481A2 COMPOUNDS AND RELATED METHODS FOR MUTANT p53 REACTIVATION
05/12/2005WO2005014537A3 Tetrahydropyran heterocyclic cyclopentyl heteroaryl modulators of chemokine receptor activity
05/12/2005WO2005009948A3 Peptide inhibitors of beta-lactamases
05/12/2005WO2005000803A8 Asymmetric urea compound and process for producing asymmetric compound by asymmetric conjugate addition reaction with the same as catalyst
05/12/2005WO2004106297A3 Nonionic surfactant compositions
05/12/2005WO2004101510A3 Polymorphs of cabergoline
05/12/2005WO2004089312A3 New piperidinylamino-thieno[2,3-d] pyrimidine compounds
05/12/2005US20050101788 Method for manufacture of sertindole
05/12/2005US20050101651 Viricides; protease inbhibitors; useful for inhibiting the activity of picornaviral 3C proteases; for example, 6-carbamoyl-4S-{2S-[(5-naphthalen-1-yl-1H-pyrrole-2-carbonyl)-amino-3-phenyl-propionylamino}-hex-2(trans)-enoic acid ethyl ester
05/12/2005US20050101628 Useful in the prevention or treatment of certain inflammatory and immunoregulatory disorders and diseases, allergic diseases, atopic conditions including allergic rhinitis, dermatitis, conjunctivitis, and asthma, as well as autoimmune pathologies
05/12/2005US20050101626 Imidazo-fused oxazolo[4,5-beta]pyridine and imidazo-fused thiazolo[4,5-beta]pyridine based tricyclic compounds and pharmaceutical compositions comprising same
05/11/2005EP1363899B1 Quinazolone derivatives as alpha 1a/b adrenergic receptor antagonists
05/11/2005EP0971898B1 Substituted isoquinolines as ultra short acting neuromuscular blockers
05/11/2005CN1615306A C-5 modified indazolylpyrrolotriazines
05/11/2005CN1615166A Device for mini-invasive ultrasound treatment of an object by a heat-isolated transducer
05/11/2005CN1615133A Crystalline solids of carvedilol and processes for their preparation
05/11/2005CN1200940C Triazole pyrimidine compounds
05/11/2005CN1200939C Novel tetrahydropyridines, preparation method and pharmaceutical compositions containing same
05/11/2005CN1200930C New crystalline polymorphic form of 1-methyl-5-P-toluoylpyrroel-2-ac-etamidoacetic acid guaiacyl ester (MED 15)
05/10/2005US6890927 Tartrate salts of 5,8, 14-triazateracyclo[10.3.1.02,11 04.9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof
05/10/2005US6890922 For treatment of erectile dysfunction as well as female sexual dysfunction, incontinence, and hypertrophy of the prostate; inhibitors of cGMP-metabolizing phosphodiesterases (cGMP= cyclic guanosine monophosphate)
05/06/2005WO2005040107A2 Methods for making simvastatin and intermediates
05/06/2005WO2005009949A3 17-acetamido-4-azasteroid derivatives as androgen receptor modulators
05/06/2005WO2004080960A3 Methods and compositions for the enzymatic synthesis of gangliosides
05/06/2005WO2004067505A3 Bismuth dithiocarbamate compounds and uses thereof
05/06/2005WO2004065363A3 Computational design of a water-soluble analog of a protein, such as phospholamban and potassium channel kcsa
05/06/2005CA2543348A1 Methods for making simvastatin and intermediates
05/05/2005US20050096229 Biocidal compounds and their preparation
05/04/2005EP1528061A1 Heterocyclic derivatives which inhibit factor Xa
05/04/2005CN1612876A Derivatives of 5-(pyridin-3-yl)-1-azabicyclo[3.2.1] octane, the preparation thereof and the application of same in therapeutics
05/03/2005US6887905 Treatment of depression or generalized anxiety disorder
05/03/2005US6887893 Methods and compositions for treatment and prevention of tumors, tumor-related disorders and cachexia
05/03/2005US6887881 For use as antiarrhythmic drug
05/03/2005CA2149886C Process for preparing tetrazolyl-benzopyranones
04/2005
04/28/2005WO2005037834A1 NOVEL TETRAYDROSPIRO{PIPERIDINE-2,7’ -PYRROLO[3,2-b]PYRIDINE DERIVATIVES AND NOVEL INDOLE DERIVATIVES USEFUL IN THE TREATMENT OF 5-HT6 RECEPTOR -RELATED DISORDERS
04/28/2005WO2005037814A1 Novel tricyclic spiroderivatives as modulators of chemokine receptor activity
04/28/2005WO2005037784A2 Crystalline form of gamma-aminobutyric acid analog
04/28/2005WO2005037052A2 Binding assay with labelled bispidine variant
04/28/2005WO2005021495A3 Quaternary salt derivatives of 1,4-diphenylazetidin-2-ones
04/28/2005WO2005016877A3 Pyrazole carboxamides as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1
04/28/2005WO2004092125A3 Using alkylmetal reagents for directed metalation of azaaromatics
04/28/2005WO2004083170A3 Compounds, a process for their preparation and their use as dyes and pigments
04/28/2005US20050090539 Intermediates for making 1(alpha-amino-1-(cyclopropyl-fused pyrrolidinylcarbonyl)methyl)-3-hydroxyadamantanes, e.g., methyl 3-hydroxy-<a-oxotricyclo[3.3.1.13,7]decane-1-acetate
04/28/2005US20050090494 Such as N-[2-(3-{[1-(3,4-dichlorobenzylpiperidinyl]aminohydroxypropoxy)phenyl]acetamide; antiinflammatory agents, antiarthritic agents; chronic obstructive pulmonary disease, asthma, multiple sclerosis
04/28/2005CA2540861A1 Novel tetraydrospiro{piperidine-2,7' -pyrrolo[3,2-b]pyridine derivatives and novel indole derivatives useful in the treatment of 5-ht6 receptor -related disorders
04/27/2005EP1526134A2 Triazolyl tropane derivatives as ccr5 modulators
04/27/2005EP1526130A1 Substituted isoquinolines as ultra short acting neuromuscular blockers
04/27/2005EP1419150B1 Phenylsulfonyl-1,3-dihydro-2h-indole-2-one derivatives, their preparation and their therapeutic use
1 ... 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 ... 105